

December 7, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of research results at the annual meeting of 66th Japan Society for Neonatal Health and Development

-Therapeutic effects of SHED on chronic cerebral palsy model-

Tokyo, December 7, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that the research results for chronic cerebral palsy model was announced by Neonatal division, Center for Maternal-Neonatal Care, of Nagoya University Hospital (hereafter Nagoya University) at the annual meeting of 66th Japan Society for Neonatal Health and Development held from Nov. 24 to 26, 2022. KWB has been conducting R&D activities for the launch of new treatment methods for cerebral palsy with Nagoya University utilizing stem cells from human exfoliated deciduous teeth (SHED) and SHED showed improvement effects for neurological symptoms in the chronic phase, which has been challenging in cerebral palsy treatment.

Cerebral palsy is caused by a lack of oxygen and infection during pre-and postpartum period, and it has neurological symptoms such as a movement disability. Since symptoms are not often clear and it is difficult to predict symptoms immediately after childbirth (in the acute phase), there is a desire to develop new effective treatment methods even if treatment starts in the chronic phase after the acute phase and the symptoms have appeared. Studies on stem cell therapy for perinatal brain damage have mainly targeted the acute phase, and there have been no reports of animal studies showing efficacy in the chronic phase. In this study, after SHED was administered in a perinatal brain damage model with neurological symptoms, brain weight was restored, and movement disability and learning and memory disorder were improved. KWB is working hard to prepare for the launch of clinical research with the research results.

Joint patent application on the research results has been filed with Nagoya University.

Link of the 66th Japan Society for Neonatal Health and Development (Japanese only)

<http://jsnhd66.umin.jp/index.html>

Related press release:

Announcement of a patent application on cell therapy for cerebral palsy utilizing SHED
with Tokai National Higher Education and Research System

URL: https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221024_01.pdf?TabModule583=0

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com